BioCon Biologics and Civica have expanded their partnership to introduce a new Insulin Glargine medicine for patients in the United States.
The multi-year agreement aims to increase the supply of affordable insulins with Biocon Biologics manufacturing and supplying Insulin Glargine medicine to Bridgewater-based Civica.
Civica will distribute, promote, and sell the medicine in the United States under a separate Civica label and trade dress, and in California, the product will carry the CalRx brand. Biocon Biologics will continue to directly commercialize Biocon Biologics’ own Insulin Glargine-yfgn medicine, which was approved by the FDA in July 2021.
Civica President Ned McCoy praised the efficiency and goal of the partnership.
“We are pleased to expand our partnership with Biocon Biologics, which helps us achieve a significant milestone in our insulin initiative,” he said. “Today’s announcement allows us to realize our goal of bringing insulin to people who need it at a transparent low price.”
There are 38.4 million people with diabetes in the United States per the CDC, approximately 11.6 percent of the total population, with nearly a quarter being undiagnosed. An additional 97.6 million Americans have been identified as prediabetic.
BioCon CEO Shreehas Tambe was likewise enthusiastic with the partnership.
“By extending our collaboration with Civica, Inc. to include Insulin Glargine, we are building on our differentiated approach to serving and enhancing patient access—by retaining our direct commercialization and through this strategic partnership,” he said. This collaboration enables us to reach underserved populations through new channels in direct alignment with our mission.”
